Skip to main content
. Author manuscript; available in PMC: 2015 Dec 9.
Published in final edited form as: Expert Opin Ther Targets. 2015 Jun 30;19(11):1419–1422. doi: 10.1517/14728222.2015.1062879

Figure 1. Potential Therapeutic Targets in ARID1A-Mutated Cancer.

Figure 1

ARID1A-containing SWI/SNF chromatin remodeling-complex regulates multiple biological processes related to tumor suppression. A) ARID1A mutation and/or loss of expression leads to atypical signaling and cellular functions. In ARID1A-mutated cancers, the indicated pathways are potential targets that are selective against ARID1A mutation. B) To achieve a sustained clinical response, combinatorial therapies will be necessary. An EZH2 inhibitor-based approach presents a unique opportunity for combinatorial strategies.